NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free ALKS Stock Alerts $24.44 -0.21 (-0.85%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$23.89▼$24.6050-Day Range$23.76▼$32.1852-Week Range$22.01▼$33.71Volume1.31 million shsAverage Volume1.90 million shsMarket Capitalization$4.13 billionP/E Ratio11.81Dividend YieldN/APrice Target$35.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside44.7% Upside$35.38 Price TargetShort InterestHealthy7.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.45Based on 6 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-10.27%From $2.24 to $2.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.83 out of 5 starsMedical Sector73rd out of 907 stocksPharmaceutical Preparations Industry23rd out of 422 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.99% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Alkermes has recently decreased by 5.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 1.4 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Alkermes this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -10.27% in the coming year, from $2.24 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 11.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 11.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 256.59.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesApril 24, 2024 | finance.yahoo.comAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1April 21, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Stock Rating Reaffirmed by HC WainwrightApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 17, 2024 | prnewswire.comAlkermes to Report First Quarter Financial Results on May 1, 2024April 17, 2024 | finance.yahoo.comAlkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseApril 12, 2024 | markets.businessinsider.comHold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory ChallengesApril 11, 2024 | investing.comJefferies raises Alkermes stock target on positive OX2 dataApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth PotentialApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | markets.businessinsider.comBreaking Down Alkermes: 5 Analysts Share Their ViewsApril 9, 2024 | msn.comAlkermes posts early-stage win for sleeping disorder therapy (update)April 9, 2024 | seekingalpha.comAlkermes: Waking Up Narcolepsy Treatment With Promising Trial DataApril 9, 2024 | msn.comAlkermes succeeds in early-stage trial for sleeping disorder therapyApril 9, 2024 | seekingalpha.comAlkermes plc: Collecting The Fruits Of The 2023 SpinoffApril 9, 2024 | prnewswire.comAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaApril 8, 2024 | prnewswire.comAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyMarch 29, 2024 | finance.yahoo.comInvestors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three yearsMarch 28, 2024 | nasdaq.comNoteworthy Tuesday Option Activity: ALKS, DKNG, VRTMarch 20, 2024 | investing.comAlkermes exec sells over $290k in company sharesMarch 19, 2024 | msn.comBaird starts Alkermes at outperform, citing revenue streamMarch 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Alkermes In The Eyes Of 4 ExpertsMarch 18, 2024 | finance.yahoo.comInsider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)March 15, 2024 | nasdaq.comALKS Factor-Based Stock AnalysisMarch 15, 2024 | finance.yahoo.comAlkermes (ALKS) Stock Moves -0.45%: What You Should KnowMarch 7, 2024 | finanznachrichten.deAlkermes plc: Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsFebruary 27, 2024 | stocknews.comTop 3 Biotech Stocks to Consider for March ProfitsSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/25/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$35.38 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+44.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio11.81 Forward P/E Ratio10.91 P/E Growth0.66Net Income$355.76 million Net Margins21.39% Pretax Margin25.34% Return on Equity16.10% Return on Assets9.15% Debt Debt-to-Equity Ratio0.24 Current Ratio2.86 Quick Ratio2.50 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.49 Cash Flow$2.29 per share Price / Cash Flow10.69 Book Value$7.21 per share Price / Book3.39Miscellaneous Outstanding Shares169,180,000Free Float161,131,000Market Cap$4.13 billion OptionableOptionable Beta0.55 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLEidos TherapeuticsNASDAQ:EIDXAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsNew York State Teachers Retirement SystemBought 26,930 shares on 4/25/2024Ownership: 0.045%Assenagon Asset Management S.A.Sold 2,914 shares on 4/24/2024Ownership: 0.042%Simplicity Wealth LLCBought 12,145 shares on 4/24/2024Ownership: 0.007%Louisiana State Employees Retirement SystemSold 900 shares on 4/23/2024Ownership: 0.049%Paradiem LLCSold 1,162 shares on 4/23/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 10 Wall Street research analysts have issued 12-month target prices for Alkermes' shares. Their ALKS share price targets range from $25.00 to $50.00. On average, they expect the company's share price to reach $35.38 in the next twelve months. This suggests a possible upside of 44.7% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 at the beginning of the year. Since then, ALKS stock has decreased by 11.9% and is now trading at $24.44. View the best growth stocks for 2024 here. Are investors shorting Alkermes? Alkermes saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 13,520,000 shares, a decrease of 5.7% from the March 31st total of 14,340,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is currently 6.9 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ALKS earnings forecast. How can I listen to Alkermes' earnings call? Alkermes will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 15th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.51 by $0.29. The firm had revenue of $377.50 million for the quarter, compared to analysts' expectations of $362.78 million. Alkermes had a net margin of 21.39% and a trailing twelve-month return on equity of 16.10%. The company's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.02) EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), Horizon Kinetics Medical ETF (MEDX), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO) and Pacer US Small Cap Cash Cows 100 ETF (CALF). How will Alkermes' stock buyback program work? Alkermes announced that its Board of Directors has approved a stock buyback plan on Thursday, February 15th 2024, which permits the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 8.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its shares are undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.24%), Los Angeles Capital Management LLC (0.09%), Allspring Global Investments Holdings LLC (0.07%), State of Alaska Department of Revenue (0.06%), Louisiana State Employees Retirement System (0.05%) and New York State Teachers Retirement System (0.05%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
